These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38182159)

  • 1. Correction:
    Gut; 2024 Jan; 73(2):e1. PubMed ID: 38182159
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies.
    Bankwitz D; Bahai A; Labuhn M; Doepke M; Ginkel C; Khera T; Todt D; Ströh LJ; Dold L; Klein F; Klawonn F; Krey T; Behrendt P; Cornberg M; McHardy AC; Pietschmann T
    Gut; 2021 Sep; 70(9):1734-1745. PubMed ID: 33323394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B cell immunodominance in primary hepatitis C virus infection.
    Brasher NA; Eltahla AA; Underwood A; Boo I; Rizzetto S; Walker MR; Rodrigo C; Luciani F; Maher L; Drummer HE; Tedla N; Lloyd AR; Bull RA
    J Hepatol; 2020 Apr; 72(4):670-679. PubMed ID: 31785346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice.
    Alzua GP; Pihl AF; Offersgaard A; Duarte Hernandez CR; Duan Z; Feng S; Fahnøe U; Sølund C; Weis N; Law M; Prentoe JC; Christensen JP; Bukh J; Gottwein JM
    Gut; 2023 Mar; 72(3):560-572. PubMed ID: 35918103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.
    Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J
    Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study.
    Chia WN; Zhu F; Ong SWX; Young BE; Fong SW; Le Bert N; Tan CW; Tiu C; Zhang J; Tan SY; Pada S; Chan YH; Tham CYL; Kunasegaran K; Chen MI; Low JGH; Leo YS; Renia L; Bertoletti A; Ng LFP; Lye DC; Wang LF
    Lancet Microbe; 2021 Jun; 2(6):e240-e249. PubMed ID: 33778792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
    Sheward DJ; Kim C; Ehling RA; Pankow A; Castro Dopico X; Dyrdak R; Martin DP; Reddy ST; Dillner J; Karlsson Hedestam GB; Albert J; Murrell B
    Lancet Infect Dis; 2022 Jun; 22(6):813-820. PubMed ID: 35305699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus recover genotype cross-reactive neutralising antibodies to HCV during antiretroviral therapy.
    Lee S; Saraswati H; Yunihastuti E; Gani R; Price P
    Clin Immunol; 2014 Dec; 155(2):149-59. PubMed ID: 25283333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application.
    Hargreaves A; Brady C; Mellors J; Tipton T; Carroll MW; Longet S
    Pathogens; 2021 Sep; 10(9):. PubMed ID: 34578233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data.
    Nguyen D; Simmonds P; Steenhuis M; Wouters E; Desmecht D; Garigliany M; Romano M; Barbezange C; Maes P; Van Holm B; Mendoza J; Oyonarte S; Fomsgaard A; Lassaunière R; Zusinaite E; Resman Rus K; Avšič-Županc T; Reimerink JH; Brouwer F; Hoogerwerf M; Reusken CB; Grodeland G; Le Cam S; Gallian P; Amroun A; Brisbarre N; Martinaud C; Leparc Goffart I; Schrezenmeier H; Feys HB; van der Schoot CE; Harvala H
    Euro Surveill; 2021 Jul; 26(27):. PubMed ID: 34240697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 neutralising antibody therapies: Recent advances and future challenges.
    Liu M; Liang Z; Cheng ZJ; Liu L; Liu Q; Mai Y; Chen H; Lei B; Yu S; Chen H; Zheng P; Sun B
    Rev Med Virol; 2023 Sep; 33(5):e2464. PubMed ID: 37322826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
    Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
    J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Envelope-Specific IgG3 and IgG1 Responses Are Associated with Clearance of Acute Hepatitis C Virus Infection.
    Walker MR; Eltahla AA; Mina MM; Li H; Lloyd AR; Bull RA
    Viruses; 2020 Jan; 12(1):. PubMed ID: 31936235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A peptide vaccine administered transcutaneously together with cholera toxin elicits potent neutralising anti-FMDV antibody responses.
    Beignon AS; Brown F; Eftekhari P; Kramer E; Briand JP; Muller S; Partidos CD
    Vet Immunol Immunopathol; 2005 Apr; 104(3-4):273-80. PubMed ID: 15734548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis.
    Choo QL; Weiner AJ; Overby LR; Kuo G; Houghton M; Bradley DW
    Br Med Bull; 1990 Apr; 46(2):423-41. PubMed ID: 2116212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced immunosurveillance for animal morbilliviruses using vesicular stomatitis virus (VSV) pseudotypes.
    Logan N; Dundon WG; Diallo A; Baron MD; James Nyarobi M; Cleaveland S; Keyyu J; Fyumagwa R; Hosie MJ; Willett BJ
    Vaccine; 2016 Nov; 34(47):5736-5743. PubMed ID: 27742221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
    Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
    Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the E2 envelope glycoprotein of bovine viral diarrhoea virus (BVDV) elicits virus-type specific neutralising antibodies.
    Toth RL; Nettleton PF; McCrae MA
    Vet Microbiol; 1999 Mar; 65(2):87-101. PubMed ID: 10078593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study.
    Kim WJ; Choi SH; Park JY; Song JS; Chung JW; Choi ST
    Ann Rheum Dis; 2022 Nov; 81(11):1585-1593. PubMed ID: 35878999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FluoRNT: A robust, efficient assay for the detection of neutralising antibodies against yellow fever virus 17D.
    Scheck MK; Lehmann L; Zaucha M; Schwarzlmueller P; Huber K; Pritsch M; Barba-Spaeth G; Thorn-Seshold O; Krug AB; Endres S; Rothenfusser S; Thorn-Seshold J
    PLoS One; 2022; 17(2):e0262149. PubMed ID: 35139078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.